Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical ...

Palvella Therapeutics reports progress in clinical trials for QTORIN™ rapamycin, exceeding patient enrollment and anticipating significant results in upcoming years. Net loss of $8.2 million for the ...

A few years back, Matt Kaeberlein was diagnosed with a frozen shoulder. "It was really bad," he recalls. He wasn't sleeping well and couldn't throw a ball due to the pain. His doctor recommended ...

Isolated from the Streptomyces hygroscopicus bacterium, rapamycin rose to prominence as an anti-fungal and anti-cancer drug and an immunosuppressant. Several decades later, it became the target ...

Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcystic Lymphatic Malformations and Venous Malformations, among others ...

A few years back, Matt Kaeberlein was diagnosed with a frozen shoulder. "It was really bad," he recalls. He wasn't sleeping well and couldn't throw a ball due to the pain. His doctor recommended ...